Compare

AbbVie vs Pfizer

MonkScore ranges and fundamentals, side by side

Key facts

AbbVie and Pfizer: key facts

  • In fiscal 2025, AbbVie Inc. reported revenue of $61.2B and net income of $4.2B.
  • In fiscal 2025, Pfizer Inc. reported revenue of $62.6B and net income of $7.8B.
  • AbbVie Inc.'s revenue grew 2.1% a year from fiscal 2021 to fiscal 2025.
  • Pfizer Inc.'s revenue fell 6.3% a year from fiscal 2021 to fiscal 2025.
  • AbbVie Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • Pfizer Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 June 2026, AbbVie Inc. reported revenue of $64.4B and net income of $6.3B.
  • In the twelve months to 28 June 2026, Pfizer Inc. reported revenue of $63.7B and net income of $4.3B.

Side by side

AbbVie and Pfizer, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureAbbVie Inc.NYSE:ABBVPfizer Inc.NYSE:PFE
MonkScore
MonkScore range90–100as of October 202620–30as of October 2026
Sector rank64 of 628 in Healthcare520 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralDrug Manufacturers - General
Latest fiscal year
Revenue$61.2BFY 2025$62.6BFY 2025
Net income$4.2BFY 2025$7.8BFY 2025
Free cash flow$17.8BFY 2025$9.1BFY 2025
Operating cash flow$19.0BFY 2025$11.7BFY 2025
Total debt$69.1BFY 2025$67.4BFY 2025
Cash$5.2BFY 2025$1.1BFY 2025
Last 12 months
Revenue$64.4Bto 30 June 2026$63.7Bto 28 June 2026
Net income$6.3Bto 30 June 2026$4.3Bto 28 June 2026
Free cash flow$18.2Bto 30 June 2026$11.0Bto 28 June 2026
Operating cash flow$19.5Bto 30 June 2026$13.4Bto 28 June 2026
Total debt$70.8Bto 30 June 2026$63.2Bto 28 June 2026
Cash$6.6Bto 30 June 2026$976.0Mto 28 June 2026

MonkStreet provides research, not investment advice.